10 results about "Locally advanced" patented technology

The present disclosure relates to novel radiation-triggered controlled release drug compositions, and methods to make and use the radiation-triggered controlled release drug compositions. The radiation-triggered controlled drug release nanoparticle formulations may be used to achieve maximum bioavailability and minimum adverse effects of the chemo drugs in chemo radio combination therapy treatment of locally advanced solid tumors.

The application discloses application of a CDK4 / 6 inhibitor combined with oxaliplatin in preparation of a treatment drug for chemotherapy-resistant colorectal cancer. The combined use of the CDK4 / 6 inhibitor combined with oxaliplatin has excellent therapeutic effect on locally advanced rectal cancer which is resistant to a first-line chemotherapy scheme, can overcome the drug resistance of the rectal cancer patient to the chemotherapy drug, so that the tumor proliferation is inhibited, and the apoptosis of the cancer cell is promoted. The application provides a combined drug treatment scheme for neoadjuvant therapy of locally advanced rectal cancer chemotherapy resistance, can achieve the purpose of effectively treating or assisting in treating the rectal cancer, and provides a new way for treating, diagnosing or predicting the rectal cancer patient.

The present invention relates generally to methods of treating HER2-positive locally advanced or previously untreated metastatic breast cancer, and particularly provides methods of treating HER2-positive, locally advanced or previously untreated metastatic breast cancer with an anti-HER2-maytansine conjugate (e.g., trastuzumab-eimetanin) that has received prior treatment with a taxane, a method of treating a patient with locally advanced or previously untreated metastatic breast cancer.

The present disclosure relates to using ivonescimab, an anti-VEGF x anti-PD-1 bispecific antibody, optionally in combination with other therapies, to treat cancers. Disclosed embodiments include: ivonescimab or ivonescimab in combination with ligufalimab to treat head and neck squamous cell carcinoma (e.g., PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma); perioperative ivonescimab or ivonescimab in combination with chemotherapy to treat resectable non-small cell lung cancer; ivonescimab in combination with chemotherapy or in combination with ligufalimab and chemotherapy to treat colorectal cancer (e.g., recurrent or metastatic colorectal cancer); ivonescimab to treat advanced non-small cell lung cancer; and ivonescimab in combination with chemotherapy to treat locally advanced unresectable or metastatic triple-negative breast cancer.

Provided are combination therapies comprising inavolisib and a fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) for the treatment of HER2-positive cancers; and methods of treating a PIK3CA mutated, HER2 positive (HER2+) locally advanced or metastatic breast cancer comprising administering a therapeutically effective amount of inavolisib and PH FDC SC.

This invention discloses a method and system for constructing an intelligent quality control platform for radiotherapy based on multimodal data, belonging to the field of intelligent quality control technology for radiotherapy. The method includes: collaborating with at least two cross-regional medical centers to collect multimodal data from patients with locally advanced rectal cancer; performing multi-expert annotation on the target area and organs at risk on the CT images according to unified annotation standards; generating consensus annotations using a multi-annotation fusion algorithm; and forming a multi-center standardized dataset after standardization processing. It also involves the parallel construction of an automatic segmentation model, an automatic quality control module for radiotherapy planning, and a multimodal risk stratification model; integrating the automatic segmentation model, automatic quality control module, and risk stratification model into a Web-based platform; and interacting with the radiotherapy information system and radiotherapy planning system through an interface adaptation layer. This provides precise support for promoting the homogenization of radiotherapy quality and the implementation of precision radiotherapy.

A combination therapy comprising enoxacin, palbociclib, and fulvestrant is provided, along with a method for treating locally advanced or metastatic breast cancer with PIC3CA mutations, hormone receptor-positive (HR+), and HER2-negative (HER2-), the method comprising administering therapeutically effective amounts of enoxacin, palbociclib, and fulvestrant. The combination therapy produced statistically significant and clinically meaningful improvements in comparable patients compared to administration of palbociclib and fulvestrant alone.

The present invention provides methods and compositions for treating cancer (e.g., locally advanced, recurrent or metastatic solid tumors) in a subject, for example by administering to the subject an anti-cancer therapy comprising an anti-latent TGF-beta1 antibody. Also provided are compositions (e.g., anti-latent TGF-beta 1 antibodies, pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in the treatment of cancer in a subject.